-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Among the Bruton tyrosine kinase inhibitors, Acalabrutinib is more selective than Ibrutinib
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialPreviously treated CLL patients with del(17)(p13.
two
twoGroup's PFS, OS and EFS
Group's PFS, OS and EFSIn total, a total of 533 patients were randomly divided into two groups: 268 in the Acalabrutinib group and 265 in the ibrutinib group
There are 124 (46.
The occurrence of adverse events
The occurrence of adverse eventsCompared with ibrutinib, the incidence of atrial fibrillation/atrial flutter in all grades treated with Acalabrutinib was significantly reduced (9.
According to Lu compared with imatinib, for all levels of treatment of atrial fibrillation Acalabrutinib / atrial flutter occurred were significantly lower compared with imatinib according to Lu, all levels of treatment of atrial fibrillation Acalabrutinib / atrial flutter significantly lower incidence of infection
In summary, this study is the first to directly compare the low selectivity and high selectivity both long-term efficacy Bruton tyrosine kinase inhibitor therapy of CLL, proved Acalabrutinib of PFS compared with gefitinib in accordance with a non-Lu inferiority, and heart blood vessels fewer adverse events
Acalabrutinib of PFS with erlotinib according to Lu with a non-inferiority, and heart blood vessels fewer adverse events Acalabrutinib of PFS with erlotinib according to Lu with a non-inferiority, and heart blood vessels less adverse events in heart blood vessels
Original source:
Original source:Byrd John C,Hillmen Peter,Ghia Paolo et al.
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
in this message
